CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs)

Read more

CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, February 29, 2024 (GLOBE NEWSWIRE) – CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential…

Read more

CENTOGENE Explores Strategic Alternatives

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 28, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential…

Read more

CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing

Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities

Read more

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development

Read more

CENTOGENE Receives French Research Tax Credit Accreditation

Partners able to claim up to 30% tax relief

Read more

CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics

Collaboration to accelerate research to determine role of GBA gene

Read more

CENTOGENE Announces Preliminary Full Year 2023 Revenue

Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced…

Read more

CENTOGENE Announces Voting Results of Extraordinary General Meeting 2023

CAMBRIDGE, Mass. And ROSTOCK, Germany and BERLIN, December 19, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), today announced the voting…

Read more

CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. (Nasdaq: CNTG) today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT…

Read more

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads